

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting –April 10, 2013 @ 6:00 p.m.**

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. March 13, 2013 DUR Minutes – Vote
 - B. March 14, 2013 DUR Recommendation Memorandum
 - C. Correspondence

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Medication Coverage Activity for March 2013
 - B. Pharmacy Help Desk Activity for March 2013
 - C. Retrospective Drug Evaluation: Focusing on Safety

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

5. **Action Item - Vote to Prior Authorize Juvisync[®], Bydureon[®], Jentadueto[®], Janumet XR[®], Nesina[®], Kazano[®], and Oseni[®] – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

6. **Action Item – Vote to Prior Authorize Eliquis[®] and to Update Xarelto[®] Prior Authorization Criteria– See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Kuvan[®] – See Appendix E.**
A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Vote to Prior Authorize Gattex[®] – See Appendix F.**
A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **Action Item - Vote to Prior Authorize Kynamro[™] and to Update Juxtapid[™] Prior Authorization Criteria – See Appendix G.**
A. Background
B. Product Summaries
C. Cost Comparison
D. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

10. **Action Item – Intervention Strategies for Reduction of Narcotic Overprescribing – See Appendix H.**
A. Prescriber Survey
B. Narcotic Prescriber Profiling
C. Quantity Limit Reduction
D. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

11. **Fiscal Year 2012 Annual Review – See Appendix I.**
A. Top 100 Drugs by Reimbursement
B. Top 50 Drugs by Total Number of Claims
C. Expenditures by Therapeutic Class

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

12. **FDA and DEA Updates – See Appendix J.**

13. **Future Business**
A. May 2013 Meeting Cancelled
B. New Product Reviews
C. Annual Reviews

14. **Adjournment**